Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

A new study reveals that junk food and drug use are hindering life expectancy gains in the U.S., despite technological ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

It's no secret that Ozempic isn't going anywhere, but the weight loss drug category does seem to be rapidly evolving.

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.